Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up.
annual hazard
papillary thyroid cancer
radioactive iodine
recurrence
time-varying
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Dec 2020
03 Dec 2020
Historique:
received:
29
10
2020
revised:
29
11
2020
accepted:
02
12
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
9
12
2020
Statut:
epublish
Résumé
Predicting the pattern of recurrence in papillary thyroid cancer (PTC) is necessary to establish optimal surveillance and treatment strategies. We analyzed changes in hazard rate (HR) for tumor recurrence over time in 1201 unselected Middle Eastern PTC patients. The changes in risk were further analyzed according to clinical variables predictive of early (≤5 years) and late (>5 years) recurrence using Cox regression analysis to identify patient populations that remain at risk. Tumor recurrence was noted in 18.4% (221/1201) patients. The annualized hazard of PTC recurrence was highest during the first 5 years (2.8%), peaking between 1 and 2 years (3.7%), with a second smaller peak between 13 and 14 years (3.2%). Patients receiving radioactive iodine (RAI) therapy had lower recurrence hazard compared to those who did not (1.5% vs. 2.7%,
Identifiants
pubmed: 33287340
pii: cancers12123624
doi: 10.3390/cancers12123624
pmc: PMC7761718
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Endocr Relat Cancer. 2016 May;23(5):367-76
pubmed: 26917553
J Clin Endocrinol Metab. 2018 Feb 1;103(2):469-476
pubmed: 29126111
Cancers (Basel). 2019 Aug 22;11(9):
pubmed: 31443531
Medicine (Baltimore). 2015 Jul;94(26):e1063
pubmed: 26131826
Breast Cancer Res Treat. 2002 Sep;75(2):127-34
pubmed: 12243505
Thyroid. 2017 Dec;27(12):1490-1497
pubmed: 29020892
Thyroid. 2019 Jun;29(6):802-808
pubmed: 30931815
J Clin Endocrinol Metab. 2011 May;96(5):1352-9
pubmed: 21389143
Clin Cancer Res. 2014 Mar 15;20(6):1404-9
pubmed: 24501392
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32219303
PLoS One. 2020 Jun 15;15(6):e0234843
pubmed: 32542018
J Surg Oncol. 1981;17(1):9-14
pubmed: 7230834
JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020
pubmed: 28859191
Oncologist. 2013;18(2):157-62
pubmed: 23345543
Int J Cancer. 2016 Sep 1;139(5):1091-7
pubmed: 27082205
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):926-934
pubmed: 27966046
Breast Cancer Res Treat. 2009 Apr;114(3):527-35
pubmed: 18425576
Ann Saudi Med. 2008 Jul-Aug;28(4):277-81
pubmed: 18596397
Surgery. 2013 Dec;154(6):1436-46; discussion 1446-7
pubmed: 24075674
Ann Surg. 2019 May;269(5):966-971
pubmed: 29462007
Thyroid. 2018 Oct;28(10):1311-1317
pubmed: 30105948
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Thyroid. 2013 Jun;23(6):683-94
pubmed: 23742290
J Exp Med. 1972 Aug 1;136(2):261-76
pubmed: 5043412
J Clin Endocrinol Metab. 2013 Feb;98(2):636-42
pubmed: 23293334
PLoS One. 2014 Sep 09;9(9):e106668
pubmed: 25203402
JAMA Oncol. 2020 May 1;6(5):706-713
pubmed: 32134428
World J Surg. 2018 Mar;42(3):615-622
pubmed: 29349484
J Clin Endocrinol Metab. 2015 Jan;100(1):115-21
pubmed: 25337927
JAMA. 2013 Apr 10;309(14):1493-501
pubmed: 23571588
World J Surg. 2018 Feb;42(2):329-342
pubmed: 29030676
Asian Pac J Cancer Prev. 2014;15(14):5565-70
pubmed: 25081665
J Clin Oncol. 2015 Jan 1;33(1):42-50
pubmed: 25332244
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
pubmed: 18000091
J Clin Oncol. 2014 Sep 1;32(25):2718-26
pubmed: 25024077
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Clin Endocrinol (Oxf). 2013 Apr;78(4):614-20
pubmed: 22957654
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Med Oncol. 2013 Jun;30(2):514
pubmed: 23436014
Nat Clin Pract Oncol. 2007 Dec;4(12):699-710
pubmed: 18037874